Geron Bolsters Extensive Embryonic Stem Cell Patent Estate

Posted on February 7, 2008 by jrowley

Geron yesterday announced the issuance of US patent #7,326,572, helping to extend their patent protection around their embryonic stem (ES) cell platform technology in the area of treating type 1 diabetes. Currently, Geron owns an exclusive license from the Wisconsin Alumni Research Foundation (WARF) for James Tomson’s original ES patents. This license allows Geron the [...]

Filed under: Embyonic Stem Cells, Geron, Intellectual Property, Novocell, Regenerative Medicine, Type 1 diabetes | Tagged: , , , | Leave a Comment »

Celgene Strengthens Adult Stem Cell Patent Estate

Posted on January 4, 2008 by jrowley

I have recently signed up for the StemCellPatents.com weekly newsletter, and it is great to keep updated on all the patents that get issued in regenerative medicine. In the most recent newletter, they reported on two patents that issued last week that strengthen Celgene’s patent estate in adult stem cells. Celgene got into the stem [...]

Filed under: adult stem cell, Biomaterials, Celgene, Intellectual Property, placenta stem cells, Regenerative Medicine, stem cells | Tagged: , , , , | 1 Comment »

Patent Reform Act of 2007 – Impact on Regenerative Medicine

Posted on December 7, 2007 by jrowley

The author of CELLWISE, one of the newer bio-Blogs out there, asked a question related to the Patent Reform Act of 2007 in a comment on the Pfizer post. He asked: The article that is cited is right; our patent system is not optimized for today’s innovations or our different industries. The patent office is [...]

Filed under: Big Pharma, Innovation, Intellectual Property, Regenerative Medicine | Tagged: , , , , | 1 Comment »

CellCyte Issued Patent for Enhancing Cell Delivery to Cardiac Tissue

Posted on November 26, 2007 by jrowley

CellCyte Genetics Corporation recently announced that US Patent No 7,282,222 was issued, a patent which they have exclusive rights to. The press release states that the patent covers unique methods and compositions “to deliver and direct stem cells to target organs in the body”, including cardiac tissue. The focus of the patent addresses cell retention [...]

Filed under: cardiac regeneration, cell delivery, Clinical Trials, Intellectual Property, Regenerative Medicine, stem cells | 1 Comment »

  • Subscribe via email

    Subscribe to The Regeneration Station by Email

  • Top Posts

  • a

Follow

Get every new post delivered to your Inbox.